[Antitumor immuno-virotherapy with attenuated strains of measles virus]

Area of Science:

• Oncolytic virotherapy
• Immunotherapy
• Virology

Context:

• Attenuated measles virus (MeV) strains, utilized in vaccines, are explored for cancer treatment.
• MeV utilizes tumor cell receptors like CD46, CD150/SLAM, and Nectin-4 for entry.
• Tumor cells often overexpress CD46, facilitating MeV infection and evading complement-mediated lysis.
• MeV exploits defective type I interferon (IFN-I) responses in tumor cells for replication, while healthy cells are protected.

Purpose:

• To provide an update on antitumor immuno-virotherapy using attenuated measles virus (MeV).
• To highlight the mechanisms of MeV oncolytic activity and immune stimulation.
• To review the progress and results of clinical trials involving MeV-based therapies.

Summary:

• Attenuated MeV selectively infects and replicates in tumor cells, leveraging specific entry receptors and exploiting tumor-specific defects in antiviral responses.
• MeV induces immunogenic cell death, leading to the infiltration of immune cells, particularly T lymphocytes, into the tumor microenvironment.
• In vitro and in vivo studies demonstrate the oncolytic potential of attenuated MeV against various cancers.

Impact:

• Attenuated MeV-based immuno-virotherapy demonstrates significant potential as a novel cancer treatment strategy.
• Clinical trials indicate encouraging outcomes, suggesting the therapeutic efficacy of this approach.
• This research contributes to the advancement of virotherapy and cancer immunotherapy.